Vandetanib plus Docetaxel versus Docetaxel as Second-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Randomized, Double-Blind Phase III Trial (ZODIAC)
R S Herbst, Y Sun, S Korfee, P Germonpré, N Saijo, C Zhou, J Wang, P Langmuir, S J Kennedy, and B E Johnson
Final Report of a Randomized Phase II Study of Docetaxel/Oxaliplatin (DO) and Docetaxel (D) in Previously Treated Non-Small Cell Lung Cancer (NSCLC) Patients: An Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (Atom 019)
Ornella Belvedere, et al.
Sequential Chemoradiation and Radiation Alone in the Treatment of Inoperable, Locally Advanced Non-Small Cell Lung Cancer (NSCLC) and Sequential Chemoradiation and Radiation Alone in the Treatment of Inoperable, Locally Advanced Non-Small Cell Lung Cancer
Reena Davda, et al.
Outcomes of Small Cell Lung Cancer (SCLC) Patients Treated With Second-Line Chemotherapy (SL): A Retrospective Analysis of 166 Patients
Marina C. Garassino, et al.
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as Second-Line Therapy in Patients With Metastatic or Recurrent Small Cell Lung Cancer (SCLC)
Heung Tae Kim, et al.
Erlotinib Related Toxicity in Elderly Patients Affected by Non-Small-Cell Lung Cancer (NSCLC)
A. Palazzo et al.
Lapatinib With Chemotherapy in First-Line Treatment of Advanced NSCLC in Never Smokers or Seldom Smokers
R. Pandey, S. Dey, and A. Mukhopadhyay